X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1720) 1720
humans (1542) 1542
animals (1230) 1230
glucose (965) 965
male (932) 932
diabetes mellitus, type 2 - drug therapy (848) 848
diabetes (764) 764
endocrinology & metabolism (708) 708
female (625) 625
sodium-glucose transporter 2 - antagonists & inhibitors (623) 623
type 2 diabetes (617) 617
glucose - metabolism (611) 611
hypoglycemic agents - therapeutic use (573) 573
dextrose (535) 535
diabetes mellitus (476) 476
dapagliflozin (468) 468
sodium-glucose transporter 1 - metabolism (458) 458
sodium (440) 440
rats (417) 417
middle aged (409) 409
sodium-glucose transporter 1 (403) 403
sodium-glucose transporter 2 - metabolism (386) 386
double-blind (378) 378
pharmacology & pharmacy (375) 375
insulin (373) 373
glucosides - therapeutic use (372) 372
physiology (315) 315
mice (309) 309
blood glucose - metabolism (295) 295
canagliflozin (294) 294
hyperglycemia (294) 294
hypoglycemic agents - pharmacology (289) 289
hypoglycemic agents - adverse effects (287) 287
empagliflozin (281) 281
monosaccharide transport proteins - metabolism (278) 278
treatment outcome (273) 273
aged (266) 266
analysis (265) 265
expression (263) 263
sglt2 inhibitor (259) 259
adult (257) 257
benzhydryl compounds - therapeutic use (254) 254
diabetes mellitus, type 2 - blood (253) 253
glucose metabolism (248) 248
biochemistry & molecular biology (245) 245
diabetes mellitus, type 2 - metabolism (241) 241
sodium-glucose transporter 1 - genetics (241) 241
metformin (239) 239
membrane glycoproteins - metabolism (236) 236
glycemic control (235) 235
glucosides - pharmacology (234) 234
safety (232) 232
blood glucose - drug effects (225) 225
diabetes mellitus, type 2 - complications (220) 220
sodium - metabolism (219) 219
sglt1 (215) 215
type 2 diabetes mellitus (215) 215
metabolism (212) 212
blood pressure (209) 209
sodium-glucose transporter 2 inhibitors - therapeutic use (209) 209
clinical trials (208) 208
type-2 diabetes-mellitus (207) 207
glucose transporter (205) 205
risk factors (203) 203
hypoglycemic agents (197) 197
research (196) 196
kidney - metabolism (193) 193
care and treatment (192) 192
mellitus (191) 191
sglt2 inhibitors (190) 190
hypoglycemic agents - administration & dosage (189) 189
internal medicine (186) 186
inadequate glycemic control (178) 178
efficacy (177) 177
glucosides - adverse effects (171) 171
body weight (170) 170
medicine & public health (170) 170
drug therapy (163) 163
monosaccharide transport proteins - genetics (160) 160
absorption (159) 159
heart failure (158) 158
rodents (156) 156
kidney (153) 153
benzhydryl compounds - pharmacology (152) 152
cardiac & cardiovascular systems (151) 151
inhibitors (150) 150
cell biology (149) 149
diabetes therapy (149) 149
gene expression (149) 149
mortality (149) 149
physiological aspects (149) 149
transport (147) 147
biological transport (146) 146
rats, sprague-dawley (145) 145
sglt2 (143) 143
kinetics (140) 140
blood-pressure (139) 139
drug therapy, combination (138) 138
dose-response relationship, drug (137) 137
insulin resistance (137) 137
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2541) 2541
Japanese (34) 34
German (13) 13
Russian (6) 6
Spanish (6) 6
Chinese (4) 4
French (3) 3
Polish (3) 3
Korean (2) 2
Czech (1) 1
Danish (1) 1
Hungarian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 02/2013, Volume 8, Issue 2, p. e54442
.... SGLT2 inhibitors block reabsorption of filtered glucose by inhibiting SGLT2, the primary glucose transporter in the proximal tubular cell (PTC... 
MATRIX | STIMULATION | MULTIDISCIPLINARY SCIENCES | DISEASE | HIGH GLUCOSE | GENE-EXPRESSION | PPAR-GAMMA AGONISTS | TRANSFORMING GROWTH FACTOR-BETA | Diabetes Mellitus - pathology | Epithelial Cells - metabolism | Gene Expression - drug effects | Diabetes Mellitus - genetics | Transcription Factor AP-1 - genetics | Epithelial Cells - drug effects | Humans | Diabetic Nephropathies - drug therapy | NF-kappa B - metabolism | Smad3 Protein - metabolism | Transcription Factor AP-1 - metabolism | Sodium-Glucose Transporter 1 - genetics | Smad3 Protein - genetics | Sodium-Glucose Transporter 1 - metabolism | Phosphorylation - drug effects | Interleukin-6 - metabolism | Transforming Growth Factor beta1 - pharmacology | Sodium-Glucose Transporter 2 - genetics | Collagen Type IV - metabolism | Sodium-Glucose Transporter 1 - antagonists & inhibitors | Promoter Regions, Genetic | Diabetic Nephropathies - pathology | Glucosides - pharmacology | Kidney Tubules, Proximal - pathology | Interleukin-6 - genetics | Sodium-Glucose Transporter 2 - metabolism | Diabetic Nephropathies - metabolism | Diabetes Mellitus - drug therapy | Diabetes Mellitus - metabolism | Toll-Like Receptor 4 - genetics | Diabetic Nephropathies - genetics | Epithelial Cells - pathology | Glucose - pharmacology | Toll-Like Receptor 4 - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | NF-kappa B - genetics | Kidney Tubules, Proximal - metabolism | Collagen Type IV - genetics | Protein Binding | Benzhydryl Compounds - pharmacology | Kidney Tubules, Proximal - drug effects | Physiological aspects | Care and treatment | Genetic aspects | Research | Transforming growth factors | Diabetic nephropathies | Chromatin | Immunoprecipitation | Transforming growth factor-b | Interleukin | Clinical trials | Systematic review | Smad3 protein | Glucose | Kinases | Interleukin 6 | Proteins | Hyperglycemia | Rodents | Toll-like receptors | Collagen (type IV) | Hypoglycemic agents | Inhibition | Growth factors | Deoxyribonucleic acid--DNA | Immune system | Binding | Glucose transporter | Medical research | NF-κB protein | Diabetes mellitus | Markers | Activator protein 1 | Blocking | Reabsorption | Inflammation | Gene expression | Glucose transport | Medicine | High mobility group proteins | Hospitals | Inhibitors | Nephropathy | Sodium | Fibrosis | Kidney diseases | Diabetes | Transporter | Adenosine triphosphatase | Kidney transplantation | Deoxyribonucleic acid | DNA
Journal Article
Journal of Cellular Physiology, ISSN 0021-9541, 12/2007, Volume 213, Issue 3, pp. 834 - 843
Sugar consumption and subsequent sugar metabolism are known to regulate the expression of genes involved in intestinal sugar absorption and delivery... 
FRUCTOSE TRANSPORTER GLUT5 | PHYSIOLOGY | MESSENGER-RNA | MAMMALIAN SWEET | SMALL-INTESTINE | GLUCOSE SENSOR | ELEMENT-BINDING PROTEIN | SUCRASE-ISOMALTASE | TASTE RECEPTORS | UP-REGULATION | GENE-TRANSCRIPTION | CELL BIOLOGY | Cell Polarity | Glucose Transporter Type 2 - genetics | Glucose Transporter Type 5 - metabolism | Enterocytes - metabolism | Sweetening Agents - metabolism | Humans | RNA, Messenger - metabolism | Fructose - metabolism | Glucose Transporter Type 2 - metabolism | Sodium-Glucose Transporter 1 - genetics | Transfection | Cloning, Molecular | Sucrose - metabolism | Jejunum - cytology | Sodium-Glucose Transporter 1 - metabolism | Monosaccharide Transport Proteins - metabolism | Monosaccharide Transport Proteins - genetics | Oligo-1,6-Glucosidase - genetics | Caco-2 Cells | Protein Structure, Tertiary | Green Fluorescent Proteins - metabolism | Promoter Regions, Genetic | Mice, Inbred C57BL | Hexoses - metabolism | Mice, Knockout | Animals | Glucose Transporter Type 2 - chemistry | Sucrase - genetics | Glucose - metabolism | Mice | Glucose Transporter Type 5 - genetics | Green Fluorescent Proteins | Sucrose | Glucose | Cellular Biology | Tissues and Organs | Life Sciences | Jejunum | Oligo-1,6-Glucosidase | Sucrase | Food and Nutrition | Hexoses | Glucose Transporter Type 5 | Glucose Transporter Type 2 | Biochemistry, Molecular Biology | Sodium-Glucose Transporter 1 | Fructose | Human health and pathology | Enterocytes | Monosaccharide Transport Proteins | RNA, Messenger | Sweetening Agents
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 11, p. e108994
Background and Objective: Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transporter in the kidney... 
CELLS | HYPERGLYCEMIA | SGLT2 | TRANSPORTERS | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | DISEASE | INJURY | PPAR-GAMMA AGONISTS | TRANSFORMING GROWTH FACTOR-BETA | PROGRESSION | Benzoates - therapeutic use | Toll-Like Receptor 2 - genetics | Diabetic Nephropathies - etiology | Transforming Growth Factor beta1 - metabolism | Glucose Transporter Type 1 - metabolism | Male | RNA, Messenger - metabolism | Nitric Oxide Synthase Type III - deficiency | Glucosides - therapeutic use | Chemokine CCL2 - metabolism | Diabetes Mellitus, Experimental - chemically induced | Diabetes Mellitus, Experimental - complications | Diabetes Mellitus, Experimental - metabolism | Benzhydryl Compounds - therapeutic use | Diabetic Nephropathies - prevention & control | Benzimidazoles - therapeutic use | Sodium-Glucose Transporter 2 - genetics | Hypoglycemic Agents - therapeutic use | Glucosides - pharmacology | Kidney Tubules, Proximal - pathology | Albuminuria - etiology | Blood Glucose - analysis | Sodium-Glucose Transporter 2 - metabolism | Diabetic Nephropathies - metabolism | Mice, Inbred C57BL | Chemokine CCL2 - genetics | Transforming Growth Factor beta1 - genetics | Toll-Like Receptor 2 - metabolism | Nitric Oxide Synthase Type III - genetics | Fibronectins - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Mice, Knockout | Animals | Glucose Transporter Type 1 - genetics | Kidney Tubules, Proximal - metabolism | Benzoates - pharmacology | Benzimidazoles - pharmacology | Benzhydryl Compounds - pharmacology | Fibronectins - genetics | Mice | Streptozocin - toxicity | Blood Glucose - metabolism | Kidney Tubules, Proximal - drug effects | Drugs | Transcription | Syngeneic grafts | Streptozocin | Genomics | Transforming growth factor | Glucose | Macrophages | Blood | Fibronectin | Proteins | Atrophy | Hyperglycemia | Rodents | Toll-like receptors | Physiology | Inhibition | Protein transport | Immune system | Creatinine | Glucose transporter | Medical research | Kidneys | Cytokines | Diabetes mellitus | Reabsorption | Histology | Inflammation | Metabolism | Gene expression | Nephropathy | Sodium | Nitric oxide | Fibrosis | Angiotensin | Insulin resistance | Research design | Kidney diseases | Diabetes | Transporter | Monocyte chemoattractant protein 1 | Kidney transplantation | Best practice
Journal Article
American Journal of Physiology - Renal Physiology, ISSN 0363-6127, 09/2017, Volume 313, Issue 3, pp. F826 - F834
.... In the membrane fraction of the kidney, the expression of urate transporter 1 (URAT1) was significantly decreased, whereas that of ATP-binding cassette subfamily G member 2 (ABCG2... 
Hyperinsulinemia | Urate transporters | Hypouricosuria | Kidney proximal tubule | PHYSIOLOGY | hyperinsulinemia | SGLT2 INHIBITOR | GOUT | RISK | LEVEL | EXCRETION | IDENTIFICATION | hypouricosuria | DIABETES-MELLITUS | RENAL HYPOURICEMIA | urate transporters | RESISTANCE | UROLOGY & NEPHROLOGY | kidney proximal tubule | HYPERTENSION | Kidney Tubules - physiopathology | Diabetes Mellitus, Experimental - drug therapy | Streptozocin | Diabetes Mellitus, Type 1 - metabolism | Male | ATP Binding Cassette Transporter, Sub-Family G, Member 2 - metabolism | Uric Acid - urine | Renal Reabsorption - drug effects | Time Factors | Diabetes Mellitus, Type 1 - chemically induced | Diabetes Mellitus, Experimental - chemically induced | Diabetes Mellitus, Experimental - metabolism | Kidney Tubules - metabolism | Diabetes Mellitus, Experimental - physiopathology | Cell Line | Insulin - pharmacology | Glucosides - pharmacology | Uric Acid - metabolism | Kidney Tubules - drug effects | Sodium-Glucose Transporter 2 - metabolism | Diabetes Mellitus, Type 1 - physiopathology | Thiophenes - pharmacology | Renal Elimination - drug effects | Anion Transport Proteins - metabolism | Rats, Sprague-Dawley | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Diabetes Mellitus, Type 1 - drug therapy | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Animals | Blood Glucose - metabolism | Carrier proteins | Physiological aspects | Physiological research | Uric acid | Research | G proteins | Insulin | Absorption (Physiology)
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 10/2013, Volume 170, Issue 3, pp. 519 - 531
Background and Purpose Although inhibition of renal sodium–glucose co‐transporter 2 (SGLT2) has a stable glucose... 
tofogliflozin | nephropathy | beta‐cell loss | sodium–glucose co‐transporter inhibitor | sodium-glucose co-transporter inhibitor | beta-cell loss | SYSTEM | METFORMIN | SELECTIVE SGLT2 INHIBITOR | GLYCEMIC CONTROL | EFFICACY | DAPAGLIFLOZIN TREATMENT | GLOMERULAR HYPERFILTRATION | DIABETES-MELLITUS | INSULIN | PHARMACOLOGY & PHARMACY | KIDNEY | Kidney - pathology | Diabetic Nephropathies - etiology | Glycated Hemoglobin A - metabolism | Diabetes Mellitus, Type 2 - metabolism | Insulin - blood | Angiotensin II Type 1 Receptor Blockers - pharmacology | Insulin-Secreting Cells - metabolism | Kidney - metabolism | Diabetic Nephropathies - physiopathology | Time Factors | Female | Albuminuria - metabolism | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Kidney - physiopathology | Disease Models, Animal | Glucosides - pharmacology | Kidney - drug effects | Sodium-Glucose Transporter 2 - metabolism | Diabetic Nephropathies - metabolism | Losartan - pharmacology | Biomarkers - blood | Albuminuria - prevention & control | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Animals | Diabetes Mellitus, Type 2 - physiopathology | Insulin-Secreting Cells - drug effects | Benzhydryl Compounds - pharmacology | Mice | Insulin-Secreting Cells - pathology | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Glucose metabolism | Pancreatic beta cells | Image processing | Blood sugar | Analysis | Angiotensin | Equipment and supplies | Glucose | Diabetes | Sodium | Pancreas | Insulin | Rodents | Research Papers | sodium–glucose co-transporter inhibitor
Journal Article
Diabetologia, ISSN 0012-186X, 10/2018, Volume 61, Issue 10, pp. 2087 - 2097
...’ of these transporters in mice and men results in the excretion of filtered glucose in the urine. In humans, intravenous injection of the plant glucoside phlorizin also results in excretion of the full filtered glucose load... 
GLUTs | Human Physiology | SGLTs | Metabolic Diseases | Internal Medicine | Glucose | Review | Type 2 diabetes mellitus | Gliflozins | Kidney | Proximal tubule | Phlorizin | Inhibitors | Medicine & Public Health | SODIUM | FANCONI-BICKEL-SYNDROME | LOW-AFFINITY | NA+/GLUCOSE COTRANSPORTER SGLT2 | TRANSPORT | THERAPEUTIC TARGET | ENDOCRINOLOGY & METABOLISM | PHLORHIZIN | EXPRESSION | BINDING | Glucose Transporter Type 2 - genetics | Humans | Sodium-Glucose Transporter 2 Inhibitors - pharmacology | Homeostasis | Diabetes Mellitus, Type 2 - metabolism | Sodium-Glucose Transporter 1 - physiology | Sodium-Glucose Transporter 1 - genetics | Glycosuria - metabolism | Hypoglycemic Agents - pharmacology | Mice, Knockout | Sodium-Glucose Transporter 2 - physiology | Kidney - metabolism | Animals | Glucose Transporter Type 2 - physiology | Drug Design | HEK293 Cells | Kidney Tubules, Proximal - metabolism | Glucose - metabolism | Mice | Blood Glucose - metabolism | Kidney Tubules - metabolism | Phlorhizin - pharmacology | Sodium-Glucose Transporter 2 - genetics | Type 2 diabetes | Medical colleges | Analysis | Physiological aspects | Hypoglycemic agents | Dextrose | Membrane proteins | Glucose transporter | Urine | Excretion | Intravenous administration | Renal function | Kidneys | Diabetes mellitus | Reabsorption | Sodium | Physiology | Diabetes | Diabetes mellitus (non-insulin dependent)
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2012, Volume 7, Issue 2, p. e30555
Background: Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM). Methods... 
SELECTIVE SGLT2 INHIBITOR | SODIUM | HOMEOSTASIS | HYPERGLYCEMIA | DAPAGLIFLOZIN | TRANSPORTERS | MULTIDISCIPLINARY SCIENCES | INSULIN-SECRETION | COTRANSPORTER | PROXIMAL TUBULAR CELLS | T-1095 | Thiophenes - therapeutic use | Diabetes Mellitus, Experimental - drug therapy | Humans | Body Weight - drug effects | Male | Muscle, Skeletal - metabolism | Muscle, Skeletal - cytology | Hyperglycemia - drug therapy | Sodium-Glucose Transporter 1 - genetics | Muscle, Skeletal - drug effects | Hyperglycemia - pathology | Sodium-Glucose Transport Proteins - metabolism | Glucosides - therapeutic use | Weight Gain - drug effects | Sodium-Glucose Transporter 1 - metabolism | Diabetes Mellitus, Experimental - metabolism | Kidney - physiopathology | Sodium-Glucose Transport Proteins - genetics | CHO Cells | Sodium-Glucose Transporter 2 - genetics | Cricetinae | Glucose Tolerance Test | Kidney - drug effects | Sodium-Glucose Transporter 2 - metabolism | Mice, Inbred C57BL | Cells, Cultured | Rats | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hyperglycemia - metabolism | Rats, Zucker | Animals | Canagliflozin | Diabetes Mellitus, Experimental - pathology | Mice, Obese | Mice | Blood Glucose - metabolism | Type 2 diabetes | Glucose metabolism | Obesity | Blood sugar | Analysis | Body weight | Glycosylated hemoglobin | Diabetes therapy | Cell culture | Animal models | Renal function | Laboratories | Liver | Homeostasis | Fuel consumption | Diabetic neuropathy | Glucose | Oocytes | Hyperglycemia | Rodents | Hemoglobin | Glucose transporter | Excretion | Kidneys | Secretion | Research & development--R&D | Diabetes mellitus | Pharmacology | Insulin | Body weight gain | Myoblasts | Beta cells | Sodium | Weight reduction | Insulin resistance | Diabetes | Mutation | Transporter | Kidney transplantation | Pharmaceuticals | Research & development | R&D
Journal Article
American Journal of Physiology - Cell Physiology, ISSN 0363-6143, 10/2017, Volume 313, Issue 4, pp. C421 - C429
...) occurs through a facilitated glucose transport, through glucose transporter 1 (GLUT1), although other isoforms have been described at the BBB... 
Blood-brain barrier | Stem cells | Glucose | blood-brain barrier | stem cells | LOCALIZATION | glucose | PHYSIOLOGY | GLUT1 DEFICIENCY | ALZHEIMERS-DISEASE | IN-VITRO MODELS | CELL BIOLOGY | METABOLISM | NEURONS | RAT-BRAIN | BARRIER-SPECIFIC PROPERTIES | DEFICIENCY SYNDROME | HYPOTHALAMUS | Glucose Transport Proteins, Facilitative - metabolism | Blood-Brain Barrier - cytology | Glucose Transporter Type 4 - metabolism | Humans | Microvessels - metabolism | Glucose Transporter Type 1 - metabolism | Glucose Transporter Type 3 - metabolism | Sodium-Glucose Transporter 1 - genetics | Glucose Transporter Type 3 - genetics | Sodium-Glucose Transporter 1 - metabolism | Glucose Transport Proteins, Facilitative - genetics | Diffusion | Induced Pluripotent Stem Cells - metabolism | Microvessels - cytology | Cell Line | Glucose Transporter Type 4 - genetics | Induced Pluripotent Stem Cells - drug effects | Endothelial Cells - metabolism | Microvessels - drug effects | Electric Impedance | Blood-Brain Barrier - drug effects | Symporters - metabolism | Blood-Brain Barrier - metabolism | Phenotype | Glucose Transporter Type 1 - genetics | Symporters - genetics | Glucose - metabolism | Glucose Transport Proteins, Facilitative - antagonists & inhibitors | Endothelial Cells - drug effects | Physiological aspects | Glucose metabolism | Endothelium
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 09/2017, Volume 19, Issue 9, pp. 1322 - 1326
Journal Article
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 11/2017, Volume 102, Issue 11, pp. 3979 - 3989
CONTEXT:Type 2 diabetes (T2DM) is associated with a higher intestinal expression of the glucose transporters sodium/glucose cotransporter 1 (SGLT-1... 
INTESTINAL GLUCOSE-ABSORPTION | GLYCEMIC CONTROL | LIFE-STYLE | TRANSPORTER MESSENGER-RNA | ENDOCRINOLOGY & METABOLISM | PLASMA-GLUCOSE | DUAL SGLT1/SGLT2 INHIBITOR | IDENTIFY SUBJECTS |